# US 2005/0239700 A1 · Treatment of cancer using antibodies to LRRC15

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239700 A1
- Document ID: US20050239700A1
- Status: Published application
- Kind: A1
- Application number: 10/963,987
- Filed: 2004-10-14
- Published: 2005-10-27
- Earliest claimed: 2003-10-14
- Assignees: Biogen Idec Inc.
- Inventors: William Kloetzer; Karen McLachlan; Michael La Barre; Jonathon Fitchett; Robert Peach; Bill Shestowsky; Scott Glaser
- Web page: https://patentgrep.com/patent/US20050239700A1

## CPC

- C07K 16/30: from tumour cells
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to novel methods of treating or diagnosing a hyperproliferative disease or disorder in an patient, where the methods include administrating to the patient a binding molecule which binds to a cell surface-expressed glycoprotein expressed predominantly in tumor or tumor-associated cells. In particular, the therapeutic and diagnostic methods of the present invention include the use of a binding molecule, for example an antibody or immunospecific fragment thereof, which specifically binds to the human LRRC15 protein. The present invention further provides a method of isolating and identifying cell surface expressed glycoproteins expressed in tumor or tumor associated tissues, where the method includes isolating desired glycoproteins via their affinity for specific lectins.

## Claims

### Claim at position 1

1-168. (canceled)

### Claim 169

A method for treating a hyperproliferative disease or disorder in an animal, comprising administering to an animal in need of treatment a composition comprising:
a) a binding molecule which specifically binds to a gene product selected from the group consisting of:
i) an LRRC15 polypeptide consisting of amino acids 1 to 581 of SEQ ID NO:2 or a fragment thereof,
ii) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 581 of SEQ ID NO:2,
iii) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 537 of SEQ ID NO:2,
iv) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 538 of SEQ ID NO:2, and
v) an LRRC15 messenger RNA consisting essentially of nucleotides 1 to 5938 of SEQ ID NO:5 or a fragment thereof; and
b) a pharmaceutically acceptable carrier.

### Claim 170 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 1 to 538 of SEQ ID NO:2.

### Claim 171 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 1 to 537 of SEQ ID NO:2.

### Claim 172 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 22 to 581 of SEQ ID NO:2.

### Claim 173 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 22 to 538 of SEQ ID NO:2.

### Claim 174 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 22 to 537 of SEQ ID NO:2.

### Claim 175 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 127 to 157 of SEQ ID NO:2.

### Claim 176 (depends on 169)

The method of claim 169, wherein said fragment consists essentially of amino acids 480 to 509 of SEQ ID NO:2.

### Claim 177 (depends on 169)

The method of claim 169, wherein said fragment comprises one or more leucine-rich-repeat (LRR) regions selected from the group consisting of:
amino acids 51 to 75 of SEQ ID NO:2 (LRR1); amino acids 76 to 99 of SEQ ID NO:2 (LRR2); amino acids 100 to 123 of SEQ ID NO:2 (LRR3); amino acids 125 to 147 of SEQ ID NO:2 (LRR4); amino acids 148 to 171 of SEQ ID NO:2 (LRR5); amino acids 173 to 195 of SEQ ID NO:2 (LRR6); amino acids 196 to 219 of SEQ ID NO:2 (LRR7); amino acids 221 to 243 of SEQ ID NO:2 (LRR8); amino acids 244 to 267 of SEQ ID NO:2 (LRR9); amino acids 269 to 291 of SEQ ID NO:2 (LRR10); amino acids 292 to 315 of SEQ ID NO:2 (LRR11); amino acids 317 to 339 of SEQ ID NO:2 (LRR12); amino acids 340 to 363 of SEQ ID NO:2 (LRR13); amino acids 364 to 387 of SEQ ID NO:2 (LRR14); and amino acids 389 to 411 of SEQ ID NO:2 (LRR15); or one or more fragments selected from the group consisting of: amino acid 25 to amino acid 60 of SEQ ID NO:2; amino acid 85 to amino acid 95 of SEQ ID NO:2; amino acid 140 to amino acid 170 of SEQ ID NO:2; amino acid 200 to amino acid 215 of SEQ ID NO:2; amino acid 240 to amino acid 255 of SEQ ID NO:2; amino acid 365 to amino acid 380 of SEQ ID NO:2; amino acid 420 to amino acid 430 of SEQ ID NO:2; amino acid 480 to amino acid 505 of SEQ ID NO:2; amino acid 25 to amino acid 50 of SEQ ID NO:2; amino acid 75 to amino acid 115 of SEQ ID NO:2; from amino acid 145 to amino acid 175 of SEQ ID NO:2; from about amino acid 195 to about amino acid 215 of SEQ ID NO:2; from amino acid 225 to amino acid 270 of SEQ ID NO:2; about amino acid 285 to amino acid 325 of SEQ ID NO:2; from amino acid 326 to amino acid 385 of SEQ ID NO:2; from amino acid 386 to amino acid 450 of SEQ ID NO:2; and from amino acid 475 to amino acid 540 of SEQ ID NO:2.

### Claim 178 (depends on 169)

The method of claim 169, wherein said binding molecule is selected from the group consisting of a fusion protein, an agent which elicits a T-cell response, a ligand, an antibody or immunospecific fragment thereof, and a small molecule.

### Claim 179 (depends on 169)

The method of claim 169, wherein said gene product is an LRRC15 messenger RNA.

### Claim 180 (depends on 179)

The method of claim 179, wherein said binding molecule is selected from the group consisting of an antisense oligonucleotide, an siRNA, a ribozyme, and a small molecule.

### Claim 181 (depends on 178)

The method of claim 178, wherein said binding molecule is an antibody or immunospecific fragment thereof.

### Claim 182 (depends on 181)

The method of any one of claims 181, wherein said antibody or fragment thereof is monoclonal.

### Claim 183 (depends on 181)

The method of any one of claims 181, wherein said antibody or fragment thereof is humanized.

### Claim 184 (depends on 181)

The method of any one of claims 181, wherein said antibody or fragment thereof is chimeric.

### Claim 185 (depends on 181)

The method of any one of claims 181, wherein said antibody or fragment thereof is primatized.

### Claim 186 (depends on 169)

The method of claim 169, wherein said binding molecule is conjugated to an agent selected from the group consisting of cytotoxic agent, a therapeutic agent, cytostatic agent, a biological toxin, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, pharmaceutical agent, a lymphokine, a heterologous antibody or fragment thereof, a detectable label, and polyethylene glycol (PEG).

### Claim 187 (depends on 186)

The method of claim 186, wherein said cytotoxic agent is selected from the group consisting of a radionuclide, a biotoxin, an enzymatically active toxin, a cytostatic or cytotoxic therapeutic agent, a prodrugs, an immunologically active ligand, and a biological response modifier.

### Claim 188 (depends on 186)

The method of claim 186, wherein said detectable label is selected from the group consisting of an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent label, and a radioactive label.

### Claim 189 (depends on 169)

The method of claim 169, wherein said hyperproliferative disease or disorder is selected from the group consisting of cancer, a neoplasm, a tumor, a malignancy, or a metastasis thereof.

### Claim 190 (depends on 189)

The method of claim 189, wherein tumor cell proliferation is inhibited through the prevention or retardation of tumor angiogenesis.

### Claim 191 (depends on 189)

The method of claim 189, wherein tumor cell proliferation is inhibited through the prevention or retardation of tumor spread to adjacent tissues.

### Claim 192 (depends on 189)

The method of claim 189, wherein said hyperproliferative disease or disorder is a neoplasm located in the: prostate, colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, adrenal gland, parathyroid gland, pituitary gland, testicles, ovary, thymus, thyroid, eye, head, neck, central nervous system, peripheral nervous system, lymphatic system, pelvis, skin, soft tissue, spleen, thoracic region, or urogenital tract.

### Claim 193 (depends on 189)

The method of claim 189, wherein said hyperproliferative disease is cancer, said cancer selected from the group consisting of: epithelial squamous cell cancer, melanoma, leukemia, myeloma, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, renal cancer, prostate cancer, testicular cancer, thyroid cancer, and head and neck cancer.

### Claim 194 (depends on 193)

The method of claim 193, wherein said cancer is selected from the group consisting of colon cancer, lung cancer, pancreatic cancer, ovarian cancer, and breast cancer.

### Claim 195 (depends on 169)

The method of claim 169, wherein said animal is a mammal.

### Claim 196 (depends on 195)

The method of claim 195, wherein said mammal is a human.

### Claim 197

A method of detecting abnormal hyperproliferative cell growth in a patient, comprising:
(a) obtaining a biological sample from said patient;
(b) contacting said sample with a binding molecule which specifically binds to an LRRC15 gene product selected from the group consisting of:
(i) an LRRC15 polypeptide consisting of amino acids 1 to 581 of SEQ ID NO:2 or a fragment thereof,
(ii) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 581 of SEQ ID NO:2,
(iii) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 537 of SEQ ID NO:2,
(iv) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 538 of SEQ ID NO:2, and
(v) an LRRC15 messenger RNA consisting essentially of nucleotides 1 to 5938 of SEQ ID NO:5 or a fragment thereof; and
(c) assaying the expression level of said LRRC15 gene product in said sample.

### Claim 198 (depends on 197)

The method of claim 197, wherein said binding molecule is detectably labeled.

### Claim 199 (depends on 198)

The method of claim 198, wherein said label is selected from the group consisting of: an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, and a radioactive label.

### Claim 200 (depends on 197)

The method of claim 197, wherein said binding molecule is selected from the group consisting of a fusion protein, an agent which elicits a T-cell response, a ligand, an antibody or immunospecific fragment thereof, and a small molecule.

### Claim 201 (depends on 197)

The method of claim 197, wherein said gene product is an LRRC15 messenger RNA.

### Claim 202 (depends on 201)

The method of claim 201, wherein said binding molecule is selected from the group consisting of an antisense oligonucleotide, an siRNA, a ribozyme, and a small molecule.

### Claim 203 (depends on 200)

The method of claim 200, wherein said binding molecule is an antibody or immunospecific fragment thereof.

### Claim 204 (depends on 203)

The method of claim 203, wherein said antibody or fragment thereof is monoclonal.

### Claim 205 (depends on 203)

The method of claim 203, wherein said antibody or fragment thereof is humanized.

### Claim 206 (depends on 203)

The method of claim 203, wherein said antibody or fragment thereof is chimeric.

### Claim 207 (depends on 203)

The method of claim 203, wherein said antibody or fragment thereof is primatized.

### Claim 208

A method of diagnosing a hyperproliferative disease or disorder in a patient, comprising:
(a) administering to said patient a sufficient amount of a detectably labeled binding molecule which specifically binds to an LRRC15 gene product selected from the group consisting of:
(i) an LRRC15 polypeptide consisting of amino acids 1 to 581 of SEQ ID NO:2 or a fragment thereof,
(ii) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 581 of SEQ ID NO:2,
(iii) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 537 of SEQ ID NO:2,
(iv) an LRRC15 variant polypeptide at least 70% identical to an LRRC15 polypeptide fragment consisting essentially of amino acids 22 to 538 of SEQ ID NO:2, and
(v) an LRRC15 messenger RNA consisting essentially of nucleotides 1 to 5938 of SEQ ID NO:5 or a fragment thereof;
(b) waiting for a time interval following said administration to allow said binding molecule to contact said gene product; and
(c) detecting the amount of said binding molecule bound to said gene product in said patient.

### Claim 209 (depends on 208)

The method of claim 208, wherein said binding molecule comprises a label selected from the group consisting of: an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a radioactive label, a positron emitting metal, and a nonradioactive paramagnetic metal ion.

### Claim 210 (depends on 209)

The method of claim 209, wherein said labeled binding molecule is detected in said patient by a method selected from the group consisting of: computed tomography (CT), position emission tomography (PET), magnetic resonance imaging (MRI), sonography, nuclear magnetic resonance imaging (NMR), electron spin resonance imaging (ESR), detection with a radiaion responsive surgical instrument, and detection with a fluorescence responsive scanning instrument.

### Claim 211 (depends on 208)

The method of claim 208, wherein said labeled binding molecule preferentially accumulates at the location of cells which express LRRC15.

### Claim 212 (depends on 209)

The method of claim 209, wherein said binding molecule is selected from the group consisting of a fusion protein, an agent which elicits a T-cell response, a ligand, an antibody or immunospecific fragment thereof, and a small molecule.

### Claim 213 (depends on 208)

The method of claim 208, wherein said gene product is an LRRC15 messenger RNA.

### Claim 214 (depends on 213)

The method of claim 213, wherein said binding molecule is selected from the group consisting of an antisense oligonucleotide, an siRNA, a ribozyme, and a small molecule.

### Claim 215 (depends on 212)

The method of claim 212, wherein said binding molecule is an antibody or immunospecific fragment thereof.

### Claim 216 (depends on 215)

The method of claim 215, wherein said antibody or fragment thereof is monoclonal.

### Claim 217 (depends on 215)

The method of claim 215, wherein said antibody or fragment thereof is humanized.

### Claim 218 (depends on 215)

The method of claim 215, wherein said antibody or fragment thereof is chimeric.

### Claim 219 (depends on 215)

The method of claim 215, wherein said antibody or fragment thereof is primatized.
